Skip to main content
Top
Published in: Clinical and Translational Oncology 4/2014

01-04-2014 | Research Article

Comparison of tumor neovasculature-targeted paramagnetic nanoliposomes for MRI in mice xenograft models

Authors: Q.-H. Xu, J.-Y. Shi, J. Zhang, Y.-F. Sun, A. H. Chang, Y.-M. Zhao, W.-J. Cai, D. Liu, C.-C. Zhou, L.-H. Fan, B. Su

Published in: Clinical and Translational Oncology | Issue 4/2014

Login to get access

Abstract

Introduction

Neovasculature imaging is a promising approach for tumor diagnosis. We constructed tumor neovasculature targeted paramagnetic nanoliposomes with RGD10, F56, and K237 peptides, which can bind to Integrin αvβ3 and VEGFR-1, VEGFR-2, respectively, and compared their potential value as MRI contrast agents for detecting small tumors in animal models.

Materials and methods

Peptide-Ahx-palmitic acid conjugate was synthesized using Fmoc solid-phase synthesis chemistry. Targeted paramagnetic nanoliposomes were prepared by the thin film dispersion–sonication method. The tumor signal enhancements of liposome particles were evaluated by MRI in a xenograft mice model.

Results

The apparent affinity constants of RGD10, K237, and F56 peptides binding to their cell receptors were 9.15 × 107, 6.01 × 107, and 3.85 × 107 mol/L, respectively. RGD10 and K237 targeted paramagnetic nanoliposomes have shown much greater tumor-specific MRI signal enhancement in xenograft of the nude mice compared to F56 targeted paramagnetic nanoliposome. Tumor signal enhancement rate (SER %) increased 2.21 ± 0.09 and 1.82 ± 0.05 fold, respectively, for RGD10 and K237 compared to non-targeted control in T1 weighted MR image.

Conclusion

RGD10 and K237 targeted paramagnetic nanoliposomes can be developed as potential tumor-specific MRI contrast agents and are helpful for tumor detection.
Literature
1.
go back to reference Paleari L, Cesario A, Granone P, D’Angelillo RM, Russo P. Early detection of cancer: lessons from lung cancer CT screening. Thorax. 2008;63:566.PubMedCrossRef Paleari L, Cesario A, Granone P, D’Angelillo RM, Russo P. Early detection of cancer: lessons from lung cancer CT screening. Thorax. 2008;63:566.PubMedCrossRef
2.
go back to reference McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med. 2003;9:713–25.PubMedCrossRef McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med. 2003;9:713–25.PubMedCrossRef
3.
go back to reference Patel N, Harris AL, Gleeson FV, Vallis KA. Clinical imaging of tumor angiogenesis. Fut Oncol. 2012;8:1443–59.CrossRef Patel N, Harris AL, Gleeson FV, Vallis KA. Clinical imaging of tumor angiogenesis. Fut Oncol. 2012;8:1443–59.CrossRef
4.
go back to reference Bertolini F, Mancuso P, Shaked Y, Kerbel RS. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Tod. 2007;12:806–12.CrossRef Bertolini F, Mancuso P, Shaked Y, Kerbel RS. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Tod. 2007;12:806–12.CrossRef
5.
go back to reference Brack SS, Dinkelborg LM, Neri D. Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imag. 2004;31:1327–41.CrossRef Brack SS, Dinkelborg LM, Neri D. Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imag. 2004;31:1327–41.CrossRef
6.
go back to reference Holig P, Bach M, Volkel T, Nahde T, Hoffmann S, Muller R, et al. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Prot Eng Des Sel. 2004;17:433–41.CrossRef Holig P, Bach M, Volkel T, Nahde T, Hoffmann S, Muller R, et al. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Prot Eng Des Sel. 2004;17:433–41.CrossRef
7.
go back to reference An P, Lei H, Zhang J, Song S, He L, Jin G, et al. Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library. Int J Can. 2004;111:165–73.CrossRef An P, Lei H, Zhang J, Song S, He L, Jin G, et al. Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library. Int J Can. 2004;111:165–73.CrossRef
8.
go back to reference Hetian L, Ping A, Shumei S, Xiaoying L, Luowen H, Jian W, et al. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem. 2002;277:43137–42.PubMedCrossRef Hetian L, Ping A, Shumei S, Xiaoying L, Luowen H, Jian W, et al. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem. 2002;277:43137–42.PubMedCrossRef
9.
go back to reference Masuho Y, Zalutsky M, Knapp RC, Bast RC Jr. Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Can Res. 1984;44:2813–9. Masuho Y, Zalutsky M, Knapp RC, Bast RC Jr. Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Can Res. 1984;44:2813–9.
10.
go back to reference Siiman O, Burshteyn A. Cell surface receptor-antibody association constants and enumeration of receptor sites for monoclonal antibodies. Cytometry. 2000;40:316–26.PubMedCrossRef Siiman O, Burshteyn A. Cell surface receptor-antibody association constants and enumeration of receptor sites for monoclonal antibodies. Cytometry. 2000;40:316–26.PubMedCrossRef
11.
go back to reference Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Meth. 1984;72:77–89.CrossRef Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Meth. 1984;72:77–89.CrossRef
12.
go back to reference Rathanaswami P, Babcook J, Gallo M. High-affinity binding measurements of antibodies to cell-surface-expressed antigens. Anal Biochem. 2008;373:52–60.PubMedCrossRef Rathanaswami P, Babcook J, Gallo M. High-affinity binding measurements of antibodies to cell-surface-expressed antigens. Anal Biochem. 2008;373:52–60.PubMedCrossRef
13.
go back to reference Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Can J. 2008;14:191–7.CrossRef Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Can J. 2008;14:191–7.CrossRef
14.
go back to reference Hsu AR, Cai W, Veeravagu A, Mohamedali KA, Chen K, Kim S, et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med. 2007;48:445–54.PubMed Hsu AR, Cai W, Veeravagu A, Mohamedali KA, Chen K, Kim S, et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med. 2007;48:445–54.PubMed
15.
go back to reference Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313–9.PubMedCrossRef Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313–9.PubMedCrossRef
16.
go back to reference Salouti M, Babaei MH, Rajabi H, Foroutan H, Rasaee MJ, Rajabi AB, et al. Comparison of (99 m) Tc-labeled PR81 and its F(ab′) fragments as radioimmunoscintigraphy agents for breast cancer imaging. Ann Nucl Med. 2011;25:87–92.PubMedCrossRef Salouti M, Babaei MH, Rajabi H, Foroutan H, Rasaee MJ, Rajabi AB, et al. Comparison of (99 m) Tc-labeled PR81 and its F(ab′) fragments as radioimmunoscintigraphy agents for breast cancer imaging. Ann Nucl Med. 2011;25:87–92.PubMedCrossRef
17.
go back to reference Iyer AK, Lan X, Zhu X, Su Y, Feng J, Zhang X, et al. Novel human single chain antibody fragments that are rapidly internalizing effectively target epithelioid and sarcomatoid mesotheliomas. Can Res. 2011;71:2428–32.CrossRef Iyer AK, Lan X, Zhu X, Su Y, Feng J, Zhang X, et al. Novel human single chain antibody fragments that are rapidly internalizing effectively target epithelioid and sarcomatoid mesotheliomas. Can Res. 2011;71:2428–32.CrossRef
18.
19.
go back to reference Dumont RA, Deininger F, Haubner R, Maecke HR, Weber WA, Fani M. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of alpha (nu) beta (3) integrin expression and facile radio synthesis. J Nucl Med. 2011;52:1276–84.PubMedCrossRef Dumont RA, Deininger F, Haubner R, Maecke HR, Weber WA, Fani M. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of alpha (nu) beta (3) integrin expression and facile radio synthesis. J Nucl Med. 2011;52:1276–84.PubMedCrossRef
20.
go back to reference Wester HJ, Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med. 2005;46:1940–5.PubMed Wester HJ, Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med. 2005;46:1940–5.PubMed
21.
go back to reference Li W, Su B, Meng S, Ju L, Yan L, Ding Y, et al. RGD-targeted paramagnetic liposomes for early detection of tumor: in vitro and in vivo studies. Eur J Radiol. 2011;80:598–606.PubMedCrossRef Li W, Su B, Meng S, Ju L, Yan L, Ding Y, et al. RGD-targeted paramagnetic liposomes for early detection of tumor: in vitro and in vivo studies. Eur J Radiol. 2011;80:598–606.PubMedCrossRef
22.
go back to reference Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Can Res. 2006;12:5018–22.CrossRef Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Can Res. 2006;12:5018–22.CrossRef
23.
go back to reference D’Amico G, Robinson SD, Germain M, Reynolds LE, Thomas GJ, Elia G, et al. Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent. PLoS One. 2010;5:e9766.PubMedCentralPubMedCrossRef D’Amico G, Robinson SD, Germain M, Reynolds LE, Thomas GJ, Elia G, et al. Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent. PLoS One. 2010;5:e9766.PubMedCentralPubMedCrossRef
24.
go back to reference Lakshmikanthan S, Sobczak M, Chun C, Henschel A, Dargatz J, Ramchandran R, et al. Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin alphavbeta. Blood. 2011;118:2015–26.PubMedCentralPubMedCrossRef Lakshmikanthan S, Sobczak M, Chun C, Henschel A, Dargatz J, Ramchandran R, et al. Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin alphavbeta. Blood. 2011;118:2015–26.PubMedCentralPubMedCrossRef
25.
go back to reference Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA. 2000;97:13003–8.PubMedCentralPubMedCrossRef Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA. 2000;97:13003–8.PubMedCentralPubMedCrossRef
26.
go back to reference Abes R, Moulton HM, Clair P, Yang ST, Abes S, Melikov K, et al. Delivery of steric block morpholino oligomers by (R-X-R) 4 peptides: structure-activity studies. Nucl Acids Res. 2008;36:6343–54.PubMedCentralPubMedCrossRef Abes R, Moulton HM, Clair P, Yang ST, Abes S, Melikov K, et al. Delivery of steric block morpholino oligomers by (R-X-R) 4 peptides: structure-activity studies. Nucl Acids Res. 2008;36:6343–54.PubMedCentralPubMedCrossRef
28.
go back to reference Meyer RD, Mohammadi M, Rahimi N. A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1. J Biol Chem. 2006;281:867–75.PubMedCentralPubMedCrossRef Meyer RD, Mohammadi M, Rahimi N. A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1. J Biol Chem. 2006;281:867–75.PubMedCentralPubMedCrossRef
29.
go back to reference Zygalaki E, Tsaroucha EG, Kaklamanis L, Lianidou ES. Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer. Clin Chem. 2007;53:1433–9.PubMedCrossRef Zygalaki E, Tsaroucha EG, Kaklamanis L, Lianidou ES. Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer. Clin Chem. 2007;53:1433–9.PubMedCrossRef
Metadata
Title
Comparison of tumor neovasculature-targeted paramagnetic nanoliposomes for MRI in mice xenograft models
Authors
Q.-H. Xu
J.-Y. Shi
J. Zhang
Y.-F. Sun
A. H. Chang
Y.-M. Zhao
W.-J. Cai
D. Liu
C.-C. Zhou
L.-H. Fan
B. Su
Publication date
01-04-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 4/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1091-4

Other articles of this Issue 4/2014

Clinical and Translational Oncology 4/2014 Go to the issue

Educational Series—Red Series

Breast cancer management in the elderly

News & Views

Obituary

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine